Status of Pradaxa Litigation

The lawsuits against the new anticoagulant drug Pradaxa from Boehringer Ingelheim Pharmaceuticals Inc. have been transferred to multidistrict litigation (MDL) to make the process easier and speedier. Many of the plaintiffs are elderly, which makes speed of the essence, and which is something that one cannot count on when filing a case against big corporations, especially pharmaceutical companies. However, even with the MDL in place, it will still take years before light becomes evident in the tunnel.

The US Judicial Panel on Multidistrict Litigation decided on the transfer on August 8, 2012, naming David R. Herndon as presiding judge and the Southern District of Illinois as the venue for the proceedings. Judge Hendron had presided previously over the MDL concerning Yaz and Yasmin. There are currently 1,617 cases with 1,690 plaintiffs which are now lumped together under MDL No. 2385 (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation).

The initial conference was held on October 3, 2012, and bellwether cases are scheduled to be established by February 2015. Bellwether cases are representative of a certain number of other cases within the MDL with similar features, and focusing on these cases will avoid duplication of arguments and speed up the process. Nevertheless, plaintiffs can expect to wait a while before any compensation will be forthcoming. The last Status Conference was held on September 18, 2013, and the next one is scheduled for October 8, 2013.

It is still possible to bring a new case for consideration of inclusion into MDL 2385. If you or a family member has been injured or died due to Pradaxa, you may be liable for compensation for the losses, pain and suffering caused by this drug. Contact a products liability lawyer with experience in dealing with pharmaceutical companies and MDL and have your case assessed.